Skip to main content
Premium Trial:

Request an Annual Quote

Nat Goodman, Rob Williamson

Premium

The Institute for Systems Biology in Seattle has hired Nat Goodman as senior research scientist. Goodman joins ISB after a stint as a freelance bioinformatics consultant. Prior to that, he was senior vice president at Cambridge, Mass.-based 3rd Millennium. Goodman will also have an appointment at the University of Alaska, Fairbanks, as affiliate professor of bioinformatics at the Arctic Region Supercomputing Center. He will continue to write his monthly “IT Guy” column for BioInform’s sister publication, Genome Technology.

Former DoubleTwist CEO Rob Williamson has landed a new job as president and COO of South San Francisco-based Eos Biotechnology.

Williamson was promoted from president to CEO of DoubleTwist in January 2002 in an unsuccessful bid to salvage the company, which closed it doors in March.

Eos CEO David Martin cited Wiliamson’s “business development, financial, and operating experience” as strengths that would aid the company’s efforts to move its pipeline of therapeutic antibodies toward the clinic.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.